[Brucella bacteremia reactivation 70 years after the primary infection].
After primary infection, some bacteria can remain in a latent state for several years before a new bacteremia, often due to a weakened immune status. This is common for Mycobacterium tuberculosis, less for other pathogens more difficult to have in mind when facing patients with fever. We report the case of an 84-year-old female patient presenting with fever in the months following antilymphoma chemotherapy, due to bacteremic brucellosis (with a hemophagocytic syndrome) probably latent after primary infection as a child.
Service de maladies infectieuses et médecine tropicale, CHU de Grenoble, BP 217, 38043 Grenoble cedex 09, France.
A
A
Meneses
O
O
Epaulard
M
M
Maurin
R
R
Gressin
P
P
Pavese
J-P
JP
Brion
B
B
Garin-Bastuji
J-P
JP
Stahl
D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D016470:Bacteremia / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology* / Q000628:therapy; D017347:Brucella melitensis; D002006:Brucellosis / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology* / Q000628:therapy; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004318:Doxycycline / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005602:France; D006801:Humans; D016867:Immunocompromised Host; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000188:drug therapy; D012008:Recurrence; D012293:Rifampin / Q000627:therapeutic use; D000069283:Rituximab; D013030:Spain / Q000208:ethnology; D013997:Time Factors; D014740:Vidarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D016756:Immunoglobulins, Intravenous; D000069283:Rituximab; D003520:Cyclophosphamide; D014740:Vidarabine; D004318:Doxycycline; C024352:fludarabine; D012293:Rifampin